Moreover, OSM-receptor (OSMR) gene expression in surgically resected samples appeared to predict worse prognosis for patients with NSCLC, and selective inhibition of JAK1/STAT3 activation and OSMR expression with JAK1 inhibitor filgotinib reversed resistance to targeted drugs [62]. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.